Aptose Biosciences Inc

Company Profile

• Business description

  Aptose Biosciences Inc is a clinical-stage biotechnology company. Its compound tuspetinib is a convenient once daily oral agent that potently targets SYK, mutated and wild-type forms of FLT3, mutated KIT, JAK1/2, and RSK2 kinases, while avoiding many typical toxicity concerns observed with other agents. The ongoing TUSCANY triplet Phase 1/2 study is designed to test various doses and schedules of TUS in combination with standard dosing of azacitidine and venetoclax in newly diagnosed patients with AML who are ineligible to receive induction chemotherapy. The group has reported data from the first three dose cohorts that demonstrated safety, CRs, and minimal residual disease (MRD) negativity across patients with diverse mutations.

• Contact

  66 Wellington Street West
  Suite 5300, TD Bank Tower Box 48
  TorontoONM5K 1E6
  CAN

  T: +1 647 479-9828

  E: [email protected]

  https://www.aptose.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2026

  Employees

  14